Document:

Form of Warrant issued by Registrant to bridge financing investors

 Exhibit 4.2 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT
BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

 HORIZON THERAPEUTICS, INC. 

WARRANT TO PURCHASE STOCK 
  

			
	[No. Bridge-]	  	    , 2009

THIS CERTIFIES THAT, for value received,
                    , with its principal office at
                    , or its successors or assigns (the “Holder”), is entitled to subscribe for and purchase from
HORIZON THERAPEUTICS, INC., a Delaware corporation (the “Company”), with its principal office at 1033 Skokie Blvd., Suite 355, Northbrook, Illinois 60062, the Exercise
Shares at the Exercise Price (each as defined and subject to adjustment as provided herein). This warrant (the “Warrant”) is being issued pursuant to the terms of the Note and Warrant Purchase Agreement, dated
October 28, 2008, as amended by that certain First Amendment to Note and Warrant Purchase Agreement dated November 20, 2008, as amended by that certain Second Amendment to Note and Warrant Purchase Agreement, dated July 2, 2009, and
as further amended by that certain Third Amendment to Note and Warrant Purchase Agreement, dated September 25, 2009, by and among the Company and the persons and entities listed on the Schedule of Purchasers thereto (as amended, the
“Purchase Agreement”) and concurrent with the issuance of the Convertible Promissory Note issued by the Company for the benefit of the Holder pursuant to the Purchase Agreement (the “Note”). Unless
indicated otherwise in this Warrant, the aggregate number of Exercise Shares that Holder may purchase by exercising this Warrant is equal to the quotient of (A) the product of (i) fifteen percent (15%) multiplied by the Third Loan
Amount under the Purchase Agreement, divided by (B) the per share price of the Exercise Shares, subject to adjustment pursuant to the terms hereof, including, but not limited to, adjustments pursuant to Section 5 below. 

1. DEFINITIONS. Capitalized terms used but not defined herein shall have the meanings set forth in the
Purchase Agreement or the Note. As used herein, the following terms shall have the following respective meanings: 
 (a)
“Exercise Period” shall mean the period commencing on the date upon which the Holder may convert the Holder’s Loan Amount into Equity Securities or Series C Stock in accordance with the Note, or, if the Holder is a
Non-Fully Participating Investor (as defined in the Purchase Agreement), upon the Non-Fully Participating Conversion (as defined in the Purchase Agreement), and ending on the earlier of (i) September 25, 2016, or (ii) the consummation
of a Corporate Transaction, unless sooner terminated as provided below. 
 (b) “Exercise Price”
shall mean (i) the per share price of Exercise Shares into which the Note is converted in connection with a Qualified Financing as provided for in Section 

 
1.2 of the Note, (ii) the per share price of Exercise Shares into which the Note is converted pursuant to Section 1.3 of the Note, or (iii) the per share price of Exercise Shares
into which the Note is converted pursuant to Section 5.2 of the Purchase Agreement, in each case subject to adjustment pursuant to Section 5 below. 

(c) “Exercise Shares” shall mean (i) if a Qualified Financing occurs and the Note issued in
connection with the issuance of this Warrant is converted as provided for in Section 1.2 of the Note, the Equity Securities sold in the Qualified Financing, (ii) if the Note issued in connection with the issuance of this Warrant is
converted as provided in Section 1.3(a) or (b) of the Note, in each of these cases, shares of Series C Stock or (iii) if the Holder becomes a Non-Fully Participating Investor pursuant to Section 5.2 of the Purchase Agreement,
shares of the Company’s Common Stock. 
 2. EXERCISE OF WARRANT.

 2.1 Cash Exercise. Subject to the terms and conditions herein, the rights represented by this Warrant may be
exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at the address set forth in Section 12 below: 

(a) An executed Notice of Exercise in the form attached hereto; 

(b) Payment of the Exercise Price either (i) in cash or by check, or (ii) by cancellation of indebtedness; and

 (c) This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased,
registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised.
In the event that this Warrant is being exercised for less than all of the then-current number of Exercise Shares purchasable hereunder, the Company shall, concurrently with the issuance by the Company of the number of Exercise Shares for which this
Warrant is then being exercised, issue a new Warrant exercisable for the remaining number of Exercise Shares purchasable hereunder. 

The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be
deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the
date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock
transfer books are open. 
 2.2 Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair
market value of one Exercise Share is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, check or cancellation of indebtedness, the Holder may elect to receive
shares equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this 

 
Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder a number of Exercise Shares computed
using the following formula: 
  

					
		 		  	X = Y (A-B)
		 		  	            A
			
		 	Where X =	  	the number of Exercise Shares to be issued to the Holder
			
		 	Y =	  	the number of Exercise Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, that portion of the Warrant being canceled (at the date of such
calculation)
			
		 	A =	  	the fair market value of one Exercise Share (at the date of such calculation)
			
		 	B =	  	Exercise Price (as adjusted to the date of such calculation)

For purposes of the above calculation, the fair market value of one Exercise Share shall be determined by the Company’s Board of
Directors in good faith; provided, however, that in the event that this Warrant is exercised pursuant to this Section 2.2 in connection with the Company’s initial public offering of its Common Stock, the fair market value per share
shall be the product of (i) the per share offering price to the public of the Company’s initial public offering, and (ii) the number of shares of Common Stock into which each Exercise Share is convertible at the time of such exercise.

 If the Holder has not exercised this Warrant prior to the expiration of this Warrant, this Warrant shall automatically be
deemed to be exercised in full in the manner set forth in Section 2, without any further action on behalf of the Holder, immediately prior to such expiration. 

3. COVENANTS OF THE COMPANY. 

3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise
of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees
that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares of equity securities comprising the Exercise Shares to provide for the exercise of the rights
represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares of such series of equity securities shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate
action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of such series of equity securities to such number of shares as shall be sufficient for such purposes. 

3.2 Notices of Record Date. In the event of any taking by the Company of a record of the holders of any class of securities for
the purpose of determining the holders thereof 

 
who are entitled to receive any dividend or other distribution, the Company shall mail to the Holder, at least ten (10) days prior to the date specified herein, a notice specifying the date
on which any such record is to be taken for the purpose of such dividend or distribution. 
 4.
REPRESENTATIONS OF HOLDER. 
 4.1 Acquisition of Warrant for Personal
Account. The Holder represents and warrants that it is acquiring the Warrant and the Exercise Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof.
The Holder also represents that the entire legal and beneficial interests of the Warrant and Exercise Shares the Holder is acquiring is being acquired for, and will be held for, its account only. 

4.2 Securities Are Not Registered. 

(a) The Holder understands that the Warrant and the Exercise Shares have not been registered under the Securities Act of 1933, as
amended (the “Act”) on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its
representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder has no such present intention. 
 (b) The Holder recognizes that the Warrant and the Exercise
Shares must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or the Exercise Shares of
the Company, or to comply with any exemption from such registration. 
 (c) The Holder is aware that neither the Warrant
nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the availability of certain current public information about the Company and the resale following the
required holding period under Rule 144. Holder is aware that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 

4.3 Disposition of Warrant and Exercise Shares. 

(a) The Holder further agrees not to make any disposition of all or any part of the Warrant or Exercise Shares in any event unless
and until: 
 (i) The Company shall have received a letter secured by the Holder from the Securities and Exchange
Commission stating that no action will be recommended to the Securities and Exchange Commission with respect to the proposed disposition; 

 (ii) There is then in effect a registration statement under the Act covering such
proposed disposition and such disposition is made in accordance with said registration statement; or 
 (iii) The Holder
shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have
furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Act or any applicable state
securities laws. The Company agrees that it will not require an opinion of counsel with respect to transactions under Rule 144 of the Act, except in unusual circumstances. 

(b) The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear the
following legend: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED. 
 4.4 Accredited Investor Status. The Holder is an “accredited investor” as
defined in Regulation D promulgated under the Act. 
 5. ADJUSTMENT OF EXERCISE
PRICE AND NUMBER OF EXERCISE SHARES. 

5.1 Changes in Securities. In the event of changes in the series of equity securities of the Company comprising the Exercise Shares
by reason of stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of Exercise Shares available under the Warrant in the
aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had the Warrant been
exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised
prior to, the consummation of a Corporate Transaction. For purposes of this Section 5, the “Aggregate Exercise Price” shall mean the aggregate Exercise Price payable in connection with the exercise in full of this
Warrant. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant. 

5.2 Automatic Conversion. Upon the automatic conversion into Common Stock of all outstanding shares of the series of equity
securities comprising the Exercise Shares, this Warrant shall become exercisable for that number of shares of Common Stock of the 

 
Company into which the Exercise Shares would then be convertible, so long as such shares, if this Warrant had been exercised prior to such offering, would have been converted into shares of the
Company’s Common Stock pursuant to the Company’s Amended and Restated Certificate of Incorporation. In such case, all references to “Exercise Shares” shall mean shares of the Company’s Common Stock issuable upon exercise of
this Warrant, as appropriate. 
 6. FRACTIONAL SHARES. No fractional shares shall be
issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) to be issued upon exercise of this Warrant shall be aggregated for purposes of determining whether the exercise
would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such
fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of one Exercise Share by such fraction. 

7. MARKET STAND-OFF AGREEMENT. Any Common Stock (or Exercise
Shares or other securities) of the Company held by Holder shall be subject to the Lock-Up Agreement provisions as set forth in Section 1.14 of that certain Investor Rights Agreement dated July 19, 2007 by and among the Company, the
Founders (as defined therein) and the Investors (as defined therein). In order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to the securities of each Holder (and the securities of every
other person subject to the restrictions in this Section 7. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 7 and shall have the right, power and authority to enforce the provisions
hereof as though they were a party hereto. 
 8. NO STOCKHOLDER
RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company. 

9. TRANSFER OF WARRANT. Subject to applicable laws and the restriction on
transfer set forth on the first page of this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any
transferee designated by Holder. The transferee shall sign an investment letter in form and substance satisfactory to the Company. 

10. LOST, STOLEN, MUTILATED OR DESTROYED
WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 11.
AMENDMENT. Any term of this Warrant may be amended or waived with the written consent of the Company and the Purchasers (as defined in the Purchase Agreement) who have agreed to lend at least sixty-seven percent
(67%) of the Total Loan Amount (as defined in the Purchase Agreement), provided, however, that no modification or waiver shall adversely affect the rights of the Holder of this Warrant in a different or disproportionate manner relative to

 
the other holders of Warrants purchased under the Purchase Agreement, unless such modification or waiver is agreed to in writing by the Holder of this Warrant. Upon the effectuation of such
amendment or waiver in conformance with this Section 11, the Company shall promptly give written notice thereof to the record holders of the Warrants who have not previously consented thereto in writing. 

12. NOTICES, ETC. All notices required or permitted hereunder shall be in writing and shall
be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at 1033 Skokie Blvd., Suite 355, Northbrook, Illinois 60062, Attn: Timothy Walbert, Fax: (224) 383-3001, Email: twalbert@horizontherapeutics.com with a copy (which shall
not constitute notice) to Cooley Godward Kronish LLP, 4401 Eastgate Mall, San Diego, CA 92121, Attn: L. Kay Chandler, Fax: (858) 550-6420, Email: kchandler@cooley.com and to Holder at
                     or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other
parties hereto. 
 13. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. 
 14. GOVERNING
LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed
entirely within the State of California without giving effect to conflicts of laws principles. 
 [SIGNATURE
PAGE FOLLOWS] 

 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer as of the date first written above. 
  

			
	HORIZON THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

[SIGNATURE PAGE TO WARRANT] 

 NOTICE OF EXERCISE 

TO: HORIZON THERAPEUTICS, INC. 

(1)        ̈      
  The undersigned hereby elects to purchase     shares of                      (the “Exercise
Shares”) of Horizon Therapeutics, Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any. 
  ̈        The
undersigned hereby elects to purchase      shares of                      (the “Exercise
Shares”) of Horizon Therapeutics, Inc. (the “Company”) pursuant to the terms of the net exercise provisions set forth in Section 2.2 of the attached Warrant, and shall tender payment of all applicable
transfer taxes, if any. 
 (2)       Please issue a certificate or certificates
representing said Exercise Shares in the name of the undersigned or in such other name as is specified below: 
  

					
		 	  
	 	
		 	(Name)	 	
		 	  
	 	
		 	  
	 	
		 	(Address)	 	
		 		 	

 (3)       The undersigned represents that (i) the
aforesaid Exercise Shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or
reselling such shares; (ii) the undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its
investment in the Company; (iii) the undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of
this investment and protecting the undersigned’s own interests; (iv) the undersigned understands that Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the
“Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein,
and, because such securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is
aware that the aforesaid Exercise Shares may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of months prescribed by Rule 144, that
among the conditions for use of the Rule is the availability of current information to the public about the Company and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not
to make any disposition of all or any part of the aforesaid shares of Exercise Shares unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in
accordance with said registration statement, or, if reasonably requested by the Company, the undersigned has provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 

 

					
	  
	 		 	  

	(Date)	 		 	(Signature)
		 		 	  

		 		 	(Print name)

  

 1. 

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form 

and supply required information. Do not use this 

form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to 
  

			
	Name:	  	  

		  	(Please Print)
		
	Address:	  	  

		  	(Please Print)

 Dated:
            , 20     
  

					
	Holder’s	 		 	
	Signature:	 	  
	 	
			
	Holder’s	 		 	
	Address:	 	  
	 	

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the
Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant. 

 

 2.Warrant issued by Registrant on December 18, 2007 to Comerica Bank

 Exhibit 4.3 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR
SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE
SECURITIES ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT AGREEMENT 

To Purchase Shares of the Series C Preferred Stock of 

HORIZON THERAPEUTICS, INC. 

Dated as of December 18, 2007 (the “Effective Date”) 

WHEREAS, Horizon Therapeutics, Inc, (the “Company”), has entered into a Loan and Security Agreement of even date
herewith (the “Loan Agreement”) with Comerica Bank (the “Warrantholder”); 
 WHEREAS, the
Company desires to grant to Warrantholder, in consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of its Series C Preferred Stack pursuant to this Warrant Agreement
(the “Warrant”); 
 NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan
Agreement and providing the financial accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE WARRANT STOCK. 

For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the
conditions hereinafter set forth, to subscribe for and purchase, from the Company, 5,626 fully paid and non-assessable shares of the Warrant Stock (as defined below) at a purchase price of $14.22 per share (the “Exercise Price”).
The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the following meanings: 

“Act” means the Securities Exchange Act of 1933, as amended. 

“Charter” means the Company’s Certificate of Incorporation, as may be amended from time to time. 

“Common Stock” means the Company’s common stock; 

“Initial Public Offering” means the initial underwritten public offering of the Company’s Common Stock pursuant to a
registration statement under the Act, which public offering has been declared effective by the Securities and Exchange Commission (“SEC”); 

“Merger Event” means a merger or consolidation involving the Company in which the Company is not the surviving entity, or
in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital of another entity, except for a merger effected exclusively for the purpose of changing the domicile of the Company
or a consolidation with a wholly-owned subsidiary of the Company. 
 “Purchase Price” means, with respect to any
exercise of this Warrant, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Warrant Stock requested to be exercised under this Warrant pursuant to such exercise. 

 

 1. 

 “Rights Agreement” means that certain Amended and Restated Investors’
Rights Agreement among the Company and certain of its shareholders dated as of July 19, 2007. 
 “Warrant
Stock” means the Series C Preferred Stock of the Company and any other stock into or for which the Series C Preferred Stock may be converted or exchanged, and upon and after the occurrence of an event which results in the automatic or
voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such Series C Preferred Stock, including, without limitation, the consummation of an Initial Public Offering of the Common Stock in which such
a conversion occurs, then from and after the date upon which such outstanding shares are so converted, redeemed or retired, “Warrant Stock” shall mean such Common Stock. 

SECTION 2. TERM OF THE WARRANT. 

Except as otherwise provided for herein, the term of this Warrant and the right to purchase Warrant Stock as granted herein shall commence
on the Effective Date and shall be exercisable for a period ending upon the earliest to occur of (i) seven (7) years from the Effective Date; (ii) five (5) years after the Initial Public Offering; or (iii) the consummation
of a Merger Event in which this Warrant is not assumed by the successor in such transaction and the consideration paid in such transaction consists of cash and/or securities of a class registered pursuant to Section 12(b) or 12(g) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”). 
 SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Warrant are exercisable by the Warrantholder, in whole or in part, at any time, or
from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”),
duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three (3) days thereafter, the Company shall issue to
the Warrantholder a certificate for the number of shares of Warrant Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the
number of shares which remain subject to future purchases, if any. 
 (i) The Purchase Price may be paid at the
Warrantholder’s election either by cash or check. 
 Upon partial exercise, the Company shall promptly issue an amended
Warrant representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Warrant shall be identical to those contained herein, including, but not limited to the Effective Date hereof. 

(b) Treatment of Warrant in the Event of a Merger Event. The Company shall give Holder written notice at least 10 days prior to the
closing of any proposed Merger Event. The Company will use commercially reasonable efforts to cause the acquirer of the Company under the Merger Event (the “Acquirer”) to assume this Warrant as a part of the Merger Event. (A) If the
Acquirer assumes this Warrant, then this Warrant shall be exercisable for the same securities, cash and property as would be payable for the Warrant Stock issuable upon exercise of the unexercised portion of this Warrant as if such Warrant Stock
were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price shall he adjusted accordingly, and the Warrant Price and number and class of Warrant Stock shall continue to be subject to adjustment from time to time
in accordance with the provisions hereof. (B) If the Acquirer refuses to assume this Warrant in connection with the Merger Event and the consideration paid in such transaction consists of cash and/or securities of a class registered pursuant to
Section 12(b) or 12(g) of the Act, the Company shall give Holder an additional written notice at least 5 days prior to the closing of the Merger Event of such fact. In such event, notwithstanding any other provision of this Warrant to the
contrary, Holder may immediately exercise this Warrant in the manner specified in this Warrant with such exercise effective immediately prior to closing of the Merger Event. If Holder elects not to exercise this Warrant, then this Warrant will
terminate immediately prior to the closing of the Merger Event. 
 SECTION 4. RESERVATION OF SHARES. 

 

 2. 

 During the term of this Warrant, the Company will at all times have authorized and reserved
a sufficient number of shares of its Warrant Stock to provide for the exercise of the rights to purchase Warrant Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for
the conversion of the Warrant Stock available hereunder. 
 SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such
fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 
 SECTION 6. NO
RIGHTS AS STOCKHOLDER. 
 This Warrant does not entitle the Warrantholder to any voting rights or other rights as a stockholder
of the Company prior to the exercise of this Warrant. 
 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Warrant. Warrantholder’s initial
address, for purposes of such registry, is set forth below Warrantholder’s signature on this Warrant. Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 

The Exercise Price and the number of shares of Warrant Stock purchasable hereunder are subject to adjustment, as follows: 

(a) Merger Event. (i) If the successor or surviving entity in a Merger Event assumes this Warrant, then this Warrant shall be
exercisable for the same securities, cash, and property as would be payable for the Warrant Stock issuable upon exercise of the unexercised portion of this Warrant as if such Warrant Stock were outstanding on the record date for the Merger Event and
subsequent closing. The Exercise Price shall be adjusted accordingly, and the Exercise Price and number and class of Warrant Stock shall continue to be subject to adjustment from time to time in accordance with the provisions hereof. 

(ii) If the consideration in such Merger Event is cash and/or securities of a class registered pursuant to
Section 12(b) or 12(g) of the Exchange Act, then the successor or surviving entity may elect not to assume this Warrant, in which case, unless the Warrantholder has otherwise exercised this Warrant, then effective immediately prior to the
closing of such Merger Event, this Warrant shall be automatically exercised pursuant to Section 3(b) above. 
 (b)
Reclassification of Shares. Except as set forth in section 8(a), if the Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights
under this Warrant exist into the same or a different number of securities of any other class or classes, this Warrant shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of
such change with respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such combination, reclassification, exchange, subdivision or other change. 

(c) Subdivision or Combination of Shares. if the Company at any time shall combine or subdivide its Warrant Stock, (i) in the
case of a subdivision, the Exercise Price shall be proportionately decreased, and the number of shares of Warrant Stock issuable upon exercise of this Warrant shall be proportionately increased, or (ii) in the case of a combination, the
Exercise Price shall be proportionately increased, and the number of shares of Warrant Stock issuable upon the exercise of this Warrant shall be proportionately decreased. 
  

 3. 

 (d) Stock Dividends. If the Company at any time while this Warrant is outstanding and
unexpired shall: 
 (i) pay a dividend with respect to the Warrant Stock payable in Warrant Stock, then the
Exercise Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of
determination by a fraction (A) the numerator of which shall be the total number of shares of Warrant Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of
shares of Warrant Stock outstanding immediately after such dividend or distribution; or 
 (ii) make any other
distribution with respect to Warrant Stock (or stock into which the Warrant Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the
Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the Warrant Stock (or other stock for which the Warrant Stock is
convertible) as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 

(e) Antidilution Rights. Additional antidilution rights applicable to the Warrant Stock purchasable hereunder are as set forth in
the Company’s Charter and shall be applicable with respect to the Warrant Stock issuable hereunder. The Company shall promptly provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter; provided,
that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Warrant Stock as of the date hereof unless such amendment, modification or waiver affects the rights of Warrantholder with respect to the
Warrant Stock in the same manner as it affects all other holders of Warrant Stock, The Company shall provide Warrantholder with prompt written notice after any issuance of any equity security issued in a bona fide financing after the Effective Date
of this Warrant, which notice shall include (a) the price at which such stock or security was sold, (b) the number of shares issued, and (c) such other information as necessary for Warrantholder to determine if a dilutive event has
occurred. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this subsection (e), the forgoing subsection (d) and the Company’s Charter. 

(f) Notice of Adjustments. If: (i) the Company shall declare any dividend or distribution upon its stock, whether in stock,
cash, property or other securities; (ii) there shall be any Merger Event; (iv) there shall be an Initial Public Offering; (iv) the Company shall sell, lease, license or otherwise transfer all or substantially all of its assets; or
(v) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall send to the Warrantholder: (A) at least ten (10) days’ prior written notice of the
date on which the books of the Company shall close or a record shall be taken for such dividend or distribution (specifying the date on which the holders of Warrant Stock shall be entitled thereto) or for determining rights to vote in respect of
such Merger Event, dissolution, liquidation or winding up; and (B) in the case of any such Merger Event, sale, lease, license or other transfer of all or substantially all assets, dissolution, liquidation or winding up, at least ten
(10) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Warrant Stock shall be entitled to exchange their Warrant Stock for securities or other property deliverable upon
such Merger Event, dissolution, liquidation or winding up). 
 Each such written notice shall set forth, in reasonable detail,
(i) the event requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the
Exercise Price has been adjusted), and (D) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall be given by first class mail, postage prepaid, or by reputable overnight courier with all charges
prepaid, addressed to the Warrantholder at the address for Warrantholder set forth in the registry referred to in Section 7. 

(g) Timely Notice. Failure to provide such notice required by subsection (f) above shall entitle Warrantholder to retain the
benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Warrantholder. For purposes of this subsection (g), and 

 

 4. 

 
notwithstanding anything to the contrary in Section 12(g), the notice period shall begin on the date Warrantholder actually receives a written notice containing all the information required
to be provided in such subsection (f). 
 SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

(a) Reservation of Warrant Stock. The Warrant Stock issuable upon exercise of the Warrantholder’s rights has been duly and
validly reserved and, when issued in accordance with the provisions of this Warrant, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever (other than those
created or imposed pursuant to the Loan Agreement); provided, that the Warrant Stock issuable pursuant to this Warrant may be subject to restrictions on transfer under state and/or federal securities laws. The Company has made available to
the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of Warrant Stock upon exercise of this Warrant shall be made without charge to the Warrantholder for any issuance tax in
respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Warrant Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of
any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 
 (b) Due
Authority. The execution and delivery by the Company of this Warrant and the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Warrant Stock and the Common
Stock into which it may be converted, have been duly authorized by all necessary corporate action on the part of the Company. This Warrant: (1) is not inconsistent with the Company’s Charter or current bylaws; (2) does not contravene
any law or governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by
which it is bound. This Warrant constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of
any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Warrant, except for the filing of notices
pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. 

(d) Issued Securities. All issued and outstanding shares of Common Stock, Preferred Stock or any other securities of the Company
have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Preferred Stock and any other securities were issued in full compliance with all federal and state securities laws. In
addition, as of the date immediately preceding the date of this Warrant: 
 (i) The authorized capital of the
Company consists of (A) 8,000,000 shares of Common Stock, of which 1,999,999 shares are issued and outstanding, (B) 1,192,118 shares of Series A Preferred Stock, all of which shares are issued and outstanding and are convertible into
1,192,118 shares of Common Stock, (C) 1,482,213 shares of Series B Preferred Stock, all of which shares are issued and outstanding and are convertible into 1,482,213 shares of Common Stock, and (D) 2,200,000 shares of Series C Preferred
Stock, of which 2,109,706 shares are issued and outstanding and are convertible into 2,109,706 shares of Common Stock. 

(ii) The Company has reserved 250,000 shares of Common Stock for issuance under its Stock Option Plan(s), under which
100,000 options are outstanding. Except for (a) the conversion privileges described in Section 9(d)(i) above and (b) the rights provided in the Rights Agreement, there are no other options, warrants, conversion privileges or other
rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock or other securities of the Company. The Company has no outstanding loans to any employee, officer or director of the
Company, and the Company agrees not to enter into any such loan or otherwise guarantee the payment of any loan made to an employee, officer or director by a third party. 
  

 5. 

 (e) Insurance. The Company has in full force and effect insurance policies, with
extended coverage, insuring the Company and its property and business against such losses and risks, and in such amounts, as are customary for corporations engaged in a similar business and similarly situated and as otherwise may be required
pursuant to the terms of any other contract or agreement. 
 (f) Other Commitments to Register Securities. Except as set
forth in this Warrant and in the Rights Agreement, the Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act any of its presently outstanding securities or any of its
securities which may hereafter be issued. 
 (g) Exempt Transaction. Subject to the accuracy of the Warrantholder’s
representations in Section 10, the issuance of the Warrant Stock upon exercise of this Warrant, and the issuance of the Common Stock upon conversion of the Warrant Stock, will each constitute a transaction exempt from (i) the registration
requirements of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws. 

(h) Compliance with Rule 144. If, after the effective date of the first registration statement filed by the Company, the
Warrantholder proposes to sell Warrant Stock issuable upon the exercise of this Warrant, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the
Company, the Company shall furnish to the Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may
be amended from time to time. 
 (i) Information Rights. During the term of this Warrant and until the Company’s
initial public offering or a Merger Event, Warrantholder shall be entitled to the information rights contain in Section 7.1 of the Loan Agreement (other than Section 7.1(e) and (f)), and Section 7.1 of the Loan Agreement is hereby
incorporated into this Warrant by this reference as though fully set forth herein, provided, however, that the Company shall not be required to deliver a Compliance Certificate once all Indebtedness (as defined in the Loan Agreement) owed by the
Company to Warrantholder as been repaid. All information will be Confidential Information subject to Section 11.2 of the Loan Agreement, which is hereby incorporated into this Warrant by this reference as though fully set forth herein and is
binding on Holder as if it were a Lender thereunder. 
 SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER.

 This Warrant has been entered into by the Company in reliance upon the following representations and covenants of the
Warrantholder: 
 (a) Investment Purpose. The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise
of the Warrantholder’s rights contained herein will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution
of the same except pursuant to a registration or exemption. 
 (b) Private Issue. The Warrantholder understands
(i) that the Warrant Stock issuable upon exercise of this Warrant is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the
registration and qualifications requirements thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 

(c) Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 
 (d)
Risk of No Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to
Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the Act is not 
  

 6. 

 
in effect when it desires to sell (i) the rights to purchase Warrant Stock pursuant to this Warrant or (ii) the Warrant Stock issuable upon exercise of the right to purchase, it may be
required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase Warrant Stock or (B) Warrant Stock issued or issuable hereunder which might be made by it
in reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 
 (e)
Accredited Investor. Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 

(f) Lock-Up Agreement. 

(i) Lock-Up Period; Agreement. In connection with the initial public offering of the Company’s securities and upon
request of the Company or the underwriters managing such offering of the Company’s securities, Warrantholder agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any of the
Company’s Common Stock (or any securities convertible into the Company’s Common Stock), however or whenever acquired (other than those included in the registration or purchased subsequent to the initial public offering) without the prior
written consent of the Company or such underwriters, as the case may he, for such period of time (not to exceed 180 days, but subject to such extension or extensions as may be required by the underwriters in order to publish research reports while
complying with the Rule 2711 of the National Association of Securities Dealers, Inc., such extension or extensions not to exceed 18 days after the expiration of such 180-day period) from the effective date of such registration statement as may be
requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the Company’s initial public offering. 

(ii) The obligations described in Section 10(f)(i) shall apply only if all officers and directors of the Company, and
all holders of the Company’s outstanding securities are bound by agreements at least as restrictive as the terms of Section 10(f)(i). 

(iii) in order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to the
securities of the Warrantholder. 
 (iv) The Warrantholder agrees that it will not transfer securities of the
Company unless each transferee agrees in writing to be bound by all of the provisions of this Section 10(f). 

(v) The Warrantholder agrees that a legend reading substantially as follows shall be placed on all certificates
representing all shares of Common Stock issued or issuable upon conversion of the Warrant Stock issuable upon exercise of this Warrant: 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS (BUT SUBJECT TO AN EXTENSION IN CERTAIN
CIRCUMSTANCES NOT TO EXCEED 18 DAYS) AFTER THE EFFECTIVE DATE OF THE ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH
MAY BE OBTAINED AT THE ISSUER’S PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 
 SECTION 11.
TRANSFERS. 
 Subject to compliance with applicable federal and state securities laws, this Warrant and all rights hereunder
are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Warrant properly endorsed. Each taker and holder of this Warrant, by taking or holding the same, consents and agrees that
this Warrant, when endorsed in blank, shall be deemed negotiable, and that the holder 
  

 7. 

 
hereof, when this Warrant shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this Warrant as the
absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Warrant. The transfer of this Warrant shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in
the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives such
Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. 
 SECTION 12. MISCELLANEOUS.

 (a) Effective Date. The provisions of this Warrant shall be construed and shall be given effect in all respects as if
it had been executed and delivered by the Company on the date hereof. This Warrant shall be binding upon any successors or assigns of the Company. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either
by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where such party will not have an adequate remedy at law and
where damages will not be readily ascertainable. Each party expressly agrees that it shall not oppose an application by the other party or any other person entitled to the benefit of this Warrant requiring specific performance of any or all
provisions hereof or enjoining such party from continuing to commit any such breach of this Warrant. 
 (c) No Impairment of
Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 

(d) Additional Documents. The Company shall also supply such other documents as the Warrantholder may from time to time reasonably
request. 
 (e) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and the
Warrantholder relating hereto, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant. For the purposes of this Section 12(e), attorneys’ fees shall
include without limitation fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding;
(iv) garnishment, levy, and debtor and third party examinations; and (v) post judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 

(f) Severability. In the event any one or more of the provisions of this Warrant shall for any reason be held invalid, illegal or
unenforceable, the remaining provisions of this Warrant shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention
of the parties underlying the invalid, illegal or unenforceable provision. 
 (g) Notices. Except as otherwise provided
herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Warrant or with respect to the subject matter hereof shall be in writing, and
shall be deemed to have been validly served, given, delivered, and received upon the earlier of; (i) the first business day after transmission by facsimile or hand delivery or deposit with an overnight express service or overnight mail delivery
service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid (provided, that any Advance Request shall not be deemed received until Lender’s actual receipt thereof), and shall be
addressed to the party to be notified as follows; 
 If to Warrantholder: 

 

 8. 

 COMERICA BANK 

Attn: Warrant Administrator 

500 Woodward Avenue,
32nd Floor, MC 3379 

Detroit, MI 48226 

If to the Company: 

Horizon Therapeutics, Inc. 

533 Bryant Street 

Palo Alto, CA 94301 

Attention: Barry Golombik 

Facsimile: 

Telephone: 
 or to such other
address as each party may designate for itself by like notice. 
 (h) Entire Agreement: Amendments. This Warrant
constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in its entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements,
whether written or oral, with respect to the subject matter hereof (including Holder’s proposal letter dated May 9, 2007). None of the terms of this Warrant may be amended except by an instrument executed by each of the parties hereto.

 (i) Headings. The various headings in this Warrant are inserted for convenience only and shall not affect the meaning
or interpretation of this Warrant or any provisions hereof. 
 (j) Advice of Counsel. Each of the parties represents to
each other party hereto that it has discussed (or had an opportunity to discuss) with its counsel this Warrant and, specifically, the provisions of Sections 12(n), 12(o), 12(p), 12(q) and 12(r). 

(k) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Warrant. In the
event an ambiguity or question of intent or interpretation arises, this Warrant shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Warrant. 
 (l) No Waiver. No omission or delay by either party at any time to
enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the other party at any time designated, shall be a waiver of any such right or remedy to which such party is entitled, nor
shall it in any way affect the right of such party to enforce such provisions thereafter. 
 (m) Survival. All
agreements, representations and warranties contained in this Warrant or in any document delivered pursuant hereto shall survive the execution and delivery of this Warrant and the expiration or other termination of this Warrant. 

(n) Governing Law. This Warrant has been negotiated and delivered to Warrantholder in the State of California, and shall have been
accepted by Warrantholder in the State of California. Delivery of Warrant Stock to Warrantholder by the Company under this Warrant is due in the State of California. This Warrant shall be governed by, and construed and enforced in accordance with,
the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

(o) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Warrant may be brought in
any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Warrant, each parry hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County,
State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this 
  

 9. 

 
Warrant. Service of process on any party hereto in any action arising out of or relating to this Warrant shall be effective if given in accordance with the requirements for notice set forth in
Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring
proceedings in the courts of any other jurisdiction. 
 (p) Mutual Waiver of Jury Trial. Because disputes arising in
connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that
their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY
OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve persons other
than the Company and Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal
relief of any kind, arising out of this Warrant. 
 (q) Judicial Reference. if the Mutual Waiver of Jury Trial set forth
in Section 12(p) is ineffective or unenforceable, the parties agree that all Claims shall be submitted to a mutually acceptable referee sitting without a jury and resolved pursuant to Code of Civil Procedure Section 638 et seq or, if there
is no mutually acceptable referee, then a referee sitting without a jury appointed by the Presiding Judge of the California Superior Court for Santa Clara County. Notwithstanding the foregoing, either party may seek from a court of competent
jurisdiction identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to
resolution by judicial reference. 
 (r) Counterparts. This Warrant and any amendments, waivers, consents or supplements
hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall he deemed an original, but all of which counterparts shall constitute but one and the same
instrument. 
 [Remainder of Page Intentionally Left Blank] 

 

 10. 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by
its officers thereunto duly authorized as of the Effective Date. 
  

							
	COMPANY:	  	HORIZON THERAPEUTICS, INC.	 	
				
		  	By:	 	 /s/ George Tidmarsh
	 	
		  	Title:	 	 CEO
	 	
				
	Notice Address:	  	Attn:	 	 Barry L. Golombik
 533
Bryant St., Suite 6
 Palo Alto, CA 94301

Facsimile: (        )
                    
	 	
			
	WARRANTHOLDER:	  	COMERICA BANK	 	
				
		  	By:	 	  
	 	
		  	Title:	 	  
	 	
			
	Notice Address:	  	Comerica Bank	 	
		  	Attn:	 	 Warrant Administrator

500 Woodward Avenue, 
32nd Floor, MC 3379

Detroit, MI 48226
	 	

  

 11. 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by
its officers thereunto duly authorized as of the Effective Date. 
  

							
	COMPANY:	  	HORIZON THERAPEUTICS, INC.	 	
				
		  	By:	 	  
	 	
		  	Title:	 	  
	 	
				
	Notice Address:	  	Attn:	 	 Barry L. Golombik
 533
Bryant St., Suite 6
 Palo Alto, CA 94301

Facsimile:
(        )                     
	 	
			
	WARRANTHOLDER:	  	COMERICA BANK	 	
				
	COMERICA BANK	  	By:	 	 /s/ [Illegible]
	 	
		  	Title:	 	 VP
	 	
			
	Notice Address:	  	Comerica Bank	 	
		  	Attn:	 	 Warrant Administrator
	 	
		  	500 Woodward Avenue, 
32nd Floor, MC 3379	 	
		  	Detroit, MI 48226	 	

  

 11. 

 EXHIBIT I 

NOTICE OF EXERCISE 
  

	To:	[                           
 ] 

  

	(1)	The undersigned Warrantholder hereby elects to purchase [    ] shares of the Series [    ] Preferred Stock of
[                    ], pursuant to the terms of the Warrant dated the [    ] day of
[            ,         ] (the “Warrant”) between
[                            ] and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of
the Purchase Price in full, together with all applicable transfer taxes, if any. 

  

	(2)	Please issue a certificate or certificates representing said shares of Series [__] Preferred Stock in the name of the undersigned or in such other name as is specified
below. 

  

	
	  

	(Name)
	  

	(Address)

  

							
	WARRANTHOLDER:	  		  	COMERICA BANK
				
		  		  	By:	 	  

				
		  		  	Title:	 	  

				
		  		  	Date:	 	  

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The
undersigned [                            ], hereby acknowledge receipt of the “Notice of
Exercise” from Comerica Bank, to purchase [    ] shares of the Series [    ] Preferred Stock of
[                    ], pursuant to the terms of the Warrant, and further acknowledges that [    ] shares remain
subject to purchase under the terms of the Warrant. 
  

							
	 COMPANY:
	 		 	HORIZON THERAPEUTICS, INC.
				
		 		 	By:	 	  

				
		 		 	Title:	 	  

				
		 		 	Date:	 	  

 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer
or assign the foregoing Warrant execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE
RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby transferred and assigned to 
  

							
	  
	  	
	(Please Print)	  	
			
	whose address is	 	  
	  	
		
	  
	  	

					
			
	Dated:	 	  
	  	

					
			
	Holder’s Signature:	 	  
	  	

					
			
	Holder’s Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]